Karo Pharma to acquire E45 Brand from Reckitt for $268m.

Karo Pharma, a portfolio of everyday healthcare products and services provider, agreed to acquire E45 Brand, a skincare expert in dry and itchy skin and treatment for eczema, psoriasis, from Reckitt, a British multinational consumer goods company, for $268m. "We are pleased to add another synergistic brand acquisition to Karo’s portfolio. E45 is a unique brand, which is trusted by consumers and represents quality and consistency. The brand will strengthen our platform in the UK market, as well as within the dermatology category, fully aligned with our strategy. Further, we will look to fuel the brand's growth via increased A&P and via injecting e-commerce capabilities recently accessed via the Sylphar transaction," Christoffer Lorenzen, Karo CEO.